CARLSBAD, Calif., July 1, 2025 /PRNewswire/ – SeqOnce, a company focused on the research, development, and commercialization of qPCR and NGS genomics tools for the Infectious Disease Research & CLIA Testing Market, has launched their
Raising $1.2M in equity SeqOnce Biosciences, Inc.’s Reg CF offering is available from Republic. Please see our company presentation and visit Republic if interested in investing at the following link. https://republic.com/seqonce About Us SeqOnce
New Research Facility to Advance Genomics SeqOnce Biosciences, Inc., a genomics company creating new tools to detect and analyze human disease, is thrilled to announce it has officially completed their move into a new facility
Next Generation Sequencing (NGS) library construction is a workflow bottleneck. The processes of library construction for DNA and RNA sequencing are complex, error prone, costly, and in general are me consuming. Current commercial products offer multistep, multi-hour sample processing that can
Next-generation sequencing is, by definition, “massively parallel.” While the first 454/Curagen GS20 systems yielded a million reads per run, the latest sequencing platforms from Illumina, (NovaSeq 6000 running their highest-capacity S4 flowcell), yields 10,000X the
